Patents Assigned to Life Sciences Research Partners vzw.
-
Publication number: 20120022135Abstract: A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2+/? mice was studied. Haplodeficiency of PHD2 did not affect tumor vessel density or lumen size, but normalized the endothelial lining and vessel maturation. This resulted in improved tumor perfusion and oxygenation, and inhibited tumor cell invasion, intravasation and metastasis. Haplodeficiency of PHD2 redirected the specification of endothelial tip cells to a more quiescent phenotype of a filopodia-lacking “phalanx” cell type. Without being bound to a particular mechanism, this transition could at least in part be explained by upregulation of (soluble) VEGFR-1 and VE-cadherin.Type: ApplicationFiled: January 20, 2010Publication date: January 26, 2012Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZWInventors: Peter Carmeliet, Massimiliano Mazzone
-
Publication number: 20110250209Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.Type: ApplicationFiled: October 2, 2009Publication date: October 13, 2011Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZWInventors: Peter Carmeliet, Sonja Loges
-
Patent number: 8003096Abstract: Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including hematopoietic and endothelial precursor cells. Conversely, antagonists of plasmin can inhibit recruitment of the stem cells. In addition, the identification of the uPA receptor (uPAR) as a retention signal for stem cells in their niche suggests a novel method for increased engraftment and isolation of multipotent stem cells.Type: GrantFiled: March 28, 2006Date of Patent: August 23, 2011Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZWInventors: Peter Carmeliet, Marc Tjwa
-
Publication number: 20110184049Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy.Type: ApplicationFiled: April 21, 2009Publication date: July 28, 2011Applicants: VIB VZW, Life Sciences Research Partners VZW, Universiteit GentInventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
-
Patent number: 7888322Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.Type: GrantFiled: November 19, 2008Date of Patent: February 15, 2011Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZWInventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
-
Patent number: 7875704Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: GrantFiled: March 24, 2006Date of Patent: January 25, 2011Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZW, Thrombogenics N.V.Inventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
-
Patent number: 7867490Abstract: The present invention relates to the field of liver diseases, more particularly to the field of portal hypertension and liver cirrhosis. The invention relates to the use of molecules which can inhibit the binding of placental growth factor (PIGF) to its receptor (VEGFR-1), such as monoclonal antibodies, for the manufacture of a medicament to treat liver cirrhosis, portal hypertension and its complications.Type: GrantFiled: June 30, 2006Date of Patent: January 11, 2011Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit GentInventors: Peter Carmeliet, Isabelle Colle, Anja Geerts
-
Patent number: 7863246Abstract: The present invention relates to the treatment of motoneuron diseases. More particularly, the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a pre-clinical ALS animal model induces a significant motor performance and prolongation of survival time of the animals.Type: GrantFiled: February 10, 2010Date of Patent: January 4, 2011Assignees: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Life Sciences Research Partners VZWInventor: Peter Carmeliet
-
Patent number: 7858593Abstract: The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and/or treatment of skeletal muscle degeneration.Type: GrantFiled: July 11, 2008Date of Patent: December 28, 2010Assignees: VIB VZW, Life Sciences Research Partners VZWInventors: Peter Carmeliet, Julián Aragonés López
-
Patent number: 7858089Abstract: The present invention relates to new antibodies and fragments and derivatives thereof. These antibodies bind to the A2 domain of Factor VIII (FVIII) of the coagulation pathway and inhibit the coagulation activity of FVIII. The antibodies are particularly suited for the characterization of the structure and function of FVIII, for the design of therapeutic strategies for eradication of FVIII inhibitors and for the use as a medicament. The invention also relates to cell lines producing the specific antibodies. The present invention furthermore relates to pharmaceutical compositions comprising the antibodies, fragments and/or derivatives of the invention and to methods of preventing and treating cardiovascular disorders by using the antibodies or fragments and derivatives thereof or pharmaceutical compositions thereof.Type: GrantFiled: July 31, 2006Date of Patent: December 28, 2010Assignee: Life Sciences Research Partners VZWInventors: Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Publication number: 20100322967Abstract: The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor.Type: ApplicationFiled: October 8, 2008Publication date: December 23, 2010Applicants: Life Sciences Research Partners VZW, VIB VZWInventors: Thierry Vandendriessche, Marinee Chuah, Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 7829085Abstract: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII.Type: GrantFiled: December 9, 2005Date of Patent: November 9, 2010Assignee: Life Sciences Research Partners VZWInventors: Marc G. Jacquemin, Jean-Marie R. Saint-Remy
-
Patent number: 7785594Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: August 16, 2004Date of Patent: August 31, 2010Assignee: Life Sciences Research Partners VZWInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20100152116Abstract: The present invention relates to the treatment of motoneuron diseases. More particularly, the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a pre-clinical ALS animal model induces a significant motor performance and prolongation of survival time of the animals.Type: ApplicationFiled: February 10, 2010Publication date: June 17, 2010Applicants: Vlaams Interuniversitair Instituut voor Biotechnologie vzw, Life Sciences Research Partners vzwInventor: Peter Carmellet
-
Patent number: 7727971Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.Type: GrantFiled: June 21, 2006Date of Patent: June 1, 2010Assignees: Life Sciences Research Partners VZW, Flanders Interuniversity Institute for Biotechnology (VIB)Inventors: Peter Carmeliet, Désiré Collen
-
Patent number: 7687463Abstract: The present invention relates to the treatment of motoneuron diseases. More particularly the invention relates to the treatment of amyotrophic lateral sclerosis (ALS). It is found that the intracerebroventricular delivery of low amounts of vascular endothelial growth factor into a preclinical ALS animal model induces a significant motor performance and prolongation of survival time of said animals.Type: GrantFiled: May 27, 2005Date of Patent: March 30, 2010Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie vzw, Life Sciences Research Partners vzwInventor: Peter Carmeliet
-
Patent number: 7615219Abstract: The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).Type: GrantFiled: January 16, 2004Date of Patent: November 10, 2009Assignee: Life Sciences Research Partners VZWInventors: Kathleen Freson, Chris Van Geet, Marc Hoylaerts
-
Publication number: 20090238826Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 10, 2009Publication date: September 24, 2009Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20090162354Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: December 22, 2008Publication date: June 25, 2009Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)Inventors: Peter CARMELIET, Desire COLLEN, Sandro DE FALCO, Ruvo MENOTTI
-
Publication number: 20090074765Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: November 5, 2008Publication date: March 19, 2009Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti